Johnson & Johnson's Q2 2014 earnings call highlighted strong performance, particularly in pharmaceuticals with the success of new products like OLYSIO driving growth.  Management conveyed confidence in the long-term healthcare market and J&J's position within it.  The call also addressed challenges in medical devices, like pricing pressures, but noted continued strength in areas such as orthopedics and global surgery.  Overall, the positive tone and strong guidance suggest a positive short-term impact on the stock price.
[1]
